title: Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor.
abstract: Endogenous opioid peptides serve as growth factors in developing, renewing, and neoplastic cells and tissues. This study examined the hypothesis that opioids serve to modulate the homeostatic renewal of ocular surface epithelium in the rat. DNA synthesis in the epithelium of the central (CC) and peripheral (PC) cornea, limbus (LM), and conjunctiva (CN) was investigated using adult male rats. Animals received an injection of opioid growth factor (OGF), [Met5]-enkephalin, OGF and naloxone (NAL), NAL alone, naltrexone (NTX), or an equivalent volume of sterile water (CO) and sacrificed 4 h later (i.e. 16:00 h). [3H]thymidine was administered 1 h before sacrifice. With the exception of NTX (20 mg/kg), all compounds were given at 10 mg/kg. Examination of 5 time points over an 18-h period revealed no variation in DNA synthesis within a region of ocular surface basal epithelium (BE). OGF depressed DNA synthesis of the BE by 25, 48, and 50% in the PC, LM, and CN, respectively; little labeling was recorded in the BE of the CC. Exposure to OGF-NAL or NAL alone did not alter DNA synthesis of the BE. Complete blockade of OGF-zeta receptor interaction by administration of the potent opioid antagonist, NTX, increased the number of epithelial cells in the PC, LM, and CN undergoing DNA synthesis by 30 to 72%. The effects of OGF and NTX on DNA synthesis of BE also were observed in an organ culture setting. Utilizing immunocytochemistry, OGF and its receptor zeta were associated with both the basal and the suprabasal cells of the ocular surface epithelium. These results indicate that an endogenous opioid peptide, OGF, and its receptor are present and govern homeostatic cellular renewal processes in ocular surface epithelium. OGF regulates DNA synthesis in a direct manner, and does so by a tonic, inhibitory, and receptor-mediated mechanism.
authors.affiliation: Department of Neuroscience and Anatomy, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey 17033, USA.
authors.forename: I S
authors.initials: IS
authors.lastname: Zagon
authors.forename: J W
authors.initials: JW
authors.lastname: Sassani
authors.forename: E R
authors.initials: ER
authors.lastname: Kane
authors.forename: P J
authors.initials: PJ
authors.lastname: McLaughlin
mesh_terms: D000818:Animals; D002940:Circadian Rhythm; D046508:Culture Techniques; D004247:DNA / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004744:Enkephalin, Methionine / Q000378:metabolism; D004847:Epithelial Cells; D004848:Epithelium / Q000378:metabolism / Q000502:physiology; D005123:Eye / Q000166:cytology / Q000378:metabolism; D006133:Growth Substances / Q000502:physiology*; D006706:Homeostasis / Q000502:physiology*; D007150:Immunohistochemistry; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009799:Ocular Physiological Phenomena; D018847:Opioid Peptides / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011957:Receptors, Opioid / Q000378:metabolism; D014018:Tissue Distribution
chemical_list: D006133:Growth Substances; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D011957:Receptors, Opioid; C062922:zeta receptor; D004744:Enkephalin, Methionine; D009271:Naltrexone; D004247:DNA